---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-007674"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:09:41.249443+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artivion Q4 revenue $116M (+19%), GAAP net income $2.4M; full year $441M

## Summary
- GAAP revenue Q4 $116.0M vs $97.3M, net income $2.4M ($0.05 diluted EPS) vs net loss $16.5M in Q4 2024.
- Adjusted revenue (ex Italian reserve) $118.3M, up 18% constant currency; adjusted EBITDA $22.7M (+29%).
- Full year 2025 GAAP revenue $441.3M vs $388.5M; GAAP net income $9.8M vs loss $13.4M.
- Filed final PMA module for AMDS Hybrid Prosthesis with FDA; positive NEXUS TRIOMPHE clinical data at STS meeting.
- Non-GAAP net income Q4 $8.6M ($0.17 per share); full year $29.7M.

## SEC filing metadata
- accession: 0001628280-26-007674
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000162828026007674/0001628280-26-007674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000162828026007674/aort-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-007674
- JSON: https://secwatch.observer/filing/0001628280-26-007674.json
- Plain text: https://secwatch.observer/filing/0001628280-26-007674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.